Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Japan's Dai-ichi Life to take 15% stake in M&G

(Sharecast News) - Japan's Dai-ichi Life Holdings is to take a major stake in investment manager M&G, it was announced on Friday, after the two firms struck a long-term strategic partnership. Under the terms of the deal, the blue chip will become Dai-chi Life's preferred asset management partner in Europe, while the mutual insurer will acquire a shareholding of around 15% in M&G.

The partnership is expected to generate at least $6bn in new business flows into funds managed by M&G over the next five years, the British firm said, and $2bn of new business flows for Dai-ichi Life.

Half of the $6bn is forecast to come from Dai-ichi Life's balance sheet on an evergreen basis, with the remaining 50% coming from joint development opportunities.

Andrea Rossi, M&G chief executive, said the deal "brings together two highly complementary international businesses with shared growth ambitions.

"It will enable us to further capitalise on the significant private market opportunities across Europe and enable even greater access to the Japanese and Asian market."

Tetsuya Kikuta, chief executive of Dai-ichi Life, said: "We see our partnership with M&G acting as a spearhead to develop our presence across Europe and the UK, accelerating our strategy to become a global top tier insurance group."

The investment, which is subject to regulatory approvals, will give Dai-ichi Life the right to appoint a director to M&G board's for as long as its holds the 15% stake.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.